OncoSignal
Live from Open Targets Platform, fetched 2026-11-11 16:03 UTC. Every row links to its source record.

TFE3 transcription factor binding to IGHM enhancer 3

ENSG00000068323 · protein coding · Open Targets profile

Transcription factor that acts as a master regulator of lysosomal biogenesis and immune response (PubMed:2338243, PubMed:24448649, PubMed:29146937, PubMed:30733432, PubMed:31672913, PubMed:37079666). Specifically recognizes and binds E-box sequences (5'-CANNTG-3'); efficient DNA-binding requires dimerization with itself or with another MiT/TFE family member such as TFEB or MITF (PubMed:24448649). Involved in the cellular response to amino acid availability by acting downstream of MTOR: in the presence of nutrients, TFE3 phosphorylation by MTOR promotes its inactivation (PubMed:24448649, PubMed:31672913, PubMed:36608670). Upon starvation or lysosomal stress, inhibition of MTOR induces TFE3 dephosphorylation, resulting in transcription factor activity (PubMed:24448649, PubMed:31672913, PubMed:36608670). Specifically recognizes and binds the CLEAR-box sequence (5'-GTCACGTGAC-3') present in the regulatory region of many lysosomal genes, leading to activate their expression, thereby playing a central role in expression of lysosomal genes (PubMed:24448649). Maintains the pluripotent state of embryonic stem cells by promoting the expression of genes such as ESRRB; mTOR- dependent TFE3 cytosolic retention and inactivation promotes exit from pluripotency (By similarity). Required to maintain the naive pluripotent state of hematopoietic stem cell; mTOR-dependent cytoplasmic retention of TFE3 promotes the exit of hematopoietic stem cell from pluripotency (PubMed:30733432). TFE3 activity is also involved in the inhibition of neuronal progenitor differentiation (By similarity). Acts as a positive regulator of browning of adipose tissue by promoting expression of target genes; mTOR-dependent phosphorylation promotes cytoplasmic retention of TFE3 and inhibits browning of adipose tissue (By similarity). In association with TFEB, activates the expression of CD40L in T-cells, thereby playing a role in T-cell- dependent antibody responses in activated CD4(+) T-cells and thymus- dependent humoral immunity (By similarity). Specifically recognizes the MUE3 box, a subset of E-boxes, present in the immunoglobulin enhancer (PubMed:2338243). It also binds very well to a USF/MLTF site (PubMed:2338243). Promotes TGF-beta-induced transcription of COL1A2; via its interaction with TSC22D1 at E-boxes in the gene proximal promoter (By similarity). May regulate lysosomal positioning in response to nutrient deprivation by promoting the expression of PIP4P1 (PubMed:29146937). {ECO:0000250|UniProtKB:Q64092, ECO:0000269|PubMed:2338243, ECO:0000269|PubMed:24448649, ECO:0000269|PubMed:29146937, ECO:0000269|PubMed:30733432, ECO:0000269|PubMed:31672913, ECO:0000269|PubMed:36608670, ECO:0000269|PubMed:37079666}.

In 13 of 15 cancers, the evidence for TFE3 comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751renal cell carcinomarenal cell carcinomarenal cell carcinoma: germline 0.56renal cell carcinoma, Xp11-associatedrenal cell carcinoma, Xp11-associatedrenal cell carcinoma, Xp11-associated: germline 0.26renal cell carcinoma associated with Xp…renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusionsrenal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions: somatic 0.61alveolar soft part sarcomaalveolar soft part sarcomaalveolar soft part sarcoma: somatic 0.61renal carcinomarenal carcinomarenal carcinoma: somatic 0.61paragangliomaparagangliomaparaganglioma: somatic 0.61alveolar rhabdomyosarcomaalveolar rhabdomyosarcomaalveolar rhabdomyosarcoma: somatic 0.61chordomachordomachordoma: somatic 0.61undifferentiated pleomorphic sarcomaundifferentiated pleomorphic sarcomaundifferentiated pleomorphic sarcoma: somatic 0.61cutaneous melanomacutaneous melanomacutaneous melanoma: somatic 0.61colon adenocarcinomacolon adenocarcinomacolon adenocarcinoma: somatic 0.61endometrial endometrioid adenocarcinomaendometrial endometrioid adenocarcinomaendometrial endometrioid adenocarcinoma: somatic 0.61melanomamelanomamelanoma: somatic 0.46head and neck squamous cell carcinomahead and neck squamous cell carcinomahead and neck squamous cell carcinoma: somatic 0.46kidney neoplasmkidney neoplasmkidney neoplasm: somatic 0.46

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

PROTAC
UniProt Ubiquitination, Database Ubiquitination

gnomAD loss of function constraint: o/e 0.14303000271320343 (upper bound 0.30074000358581543). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of TFE3's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of TFE3's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.